Skip to main content

Table 1 Results of threshold, coefficient, and endogeneity tests of base-case and two scenarios

From: Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method

 

Base-case

Scenario 1

Scenario 2

Coefficient of cost

0.611 (p < 0.001)

0.638 (p < 0.001)

0.595 (p < 0.001)

Coefficient of age

− 1.656 (p = 0.001)

− 1.678 (p < 0.001)

− 1.512 (p < 0.001)

Coefficient of 2nd line of treatment

− 0.42 (p = 0.012)

− 0.271 (p = 0.026)

− 0.464 (p < 0.001)

Durbin-Wu-Hausman (p value)

0.0162

0.0231

0.0213

Threshold (ï¿¥)

150,962

112,324

111,824

Threshold/GDP

1.86

1.39

1.38